Caxton Associates (New York)’s Amneal Pharmaceuticals AMRX Stock Holding History

Caxton Associates (New York)’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-29,150	Closed	-$243K	–	489
2024 Q3	$243K	Buy	+29,150	New	+$228K	0.01%	465
2024 Q2	–	Sell	-91,481	Closed	-$554K	–	469
2024 Q1	$554K	Buy	91,481 +8,088	+10%	+$45.6K	0.03%	307
2023 Q4	$506K	Sell	83,393 -36,887	-31%	-$164K	0.03%	320
2023 Q3	$508K	Buy	+120,280	New	+$449K	0.07%	239

Other funds holding AMRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Caxton Associates (New York)'s AMRX Position: Q4 2024 in Review

Caxton Associates (New York) sold out of Amneal Pharmaceuticals (AMRX) in Q4 2024, closing a stake of 29,150 shares — an estimated $243K sold.

Caxton Associates (New York) first reported a position in AMRX in Q3 2023 and held it in 4 quarters. The position peaked at $554K in Q1 2024. 199 funds tracked by Wall St. Rank hold AMRX as of Q4 2024.

Caxton Associates (New York) reported no remaining Amneal Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Caxton Associates (New York) sold 29,150 Amneal Pharmaceuticals shares in Q4 2024, an estimated $243K.
Caxton Associates (New York) first reported a position in Amneal Pharmaceuticals in Q3 2023 and held it in 4 quarters.
Caxton Associates (New York)'s Amneal Pharmaceuticals position peaked at $554K in Q1 2024.
199 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.